Search

Background: Globally, micronutrient use has increased over the last few decades for disease prevention and holistic health. This article has analyzed the worldwide search trends of micronutrients in the Google Trends (GT) platform to understand the significance and correlation of search trends, comparing the search interests across countries and recognizing the factors involved. Methods: Specific search terms were used to identify the search trends of micronutrients in the GT platform. Statistical analysis was done to evaluate the outcomes of significance and correlation of search terms from 2004 to 2021 by using statistical softwares. Results: There was a rise in searches for micronutrients vitamin D, vitamin C, zinc, & iron from 2004 to June 2021 with a steep increase during 2020 correlating with the COVID-19 pandemic. A stable search has been reported in iron searches. Significance and correlation of vitamin D, vitamin C, zinc, & iron over the years and search interest popularity score of countries for micronutrient searches have been described. Conclusions: The GT tool can be a necessary tool for healthcare communities and government sectors to understand people's interests, necessities and respond to their concerns accordingly, thus helping us promote population-centric awareness and achieve better evidence-based outcomes. [ABSTRACT FROM AUTHOR]

Polycystic ovary syndrome is a very common endocrine disorder prevalent in premenopausal women. Patients with polycystic ovary syndrome present with abnormal menstruation, ovulation disorders, and hyperandrogenemia. They are often accompanied by insulin resistance, metabolic disorders, and other cardiovascular abnormalities. Also, they have comorbidities, such as dyslipidemia, obesity, diabetes type 2, non-alcoholic fatty liver disease, which all influence the treatment plan. Metformin has been defined as a treatment option in patients with polycystic ovary syndrome. However, the clinical responses to metformin are limited. Thus, the need for novel treatments with a broad range of coverage for the complications is warranted. Sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, incretin analogs are novel drugs approved for treating type-2 diabetes. Because of their recorded benefit with weight loss, improved insulin resistance, and cardiovascular benefits in recent studies, they may help polycystic ovary syndrome women address the polycystic ovary syndrome-related risk of metabolic, reproductive, and psychological consequences. Limited literature is available on the safety and efficacy of these novel antidiabetic drugs in patients with polycystic ovary syndrome. Thus, this review is investigating the role and effectiveness of novel antidiabetic medication as an early therapeutic option in polycystic ovary syndrome., Competing Interests: Conflict of interests: The authors declare no conflicts of interest., (Copyright © 2022, Somagutta MR et al., Applied Systems and Discoveries Journals.)